Asahi Intecc Co Ltd
TSE:7747
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (9.1), the stock would be worth ¥3 274 (1% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.2 | ¥3 298 |
0%
|
| 3-Year Average | 9.1 | ¥3 274 |
-1%
|
| 5-Year Average | 10.8 | ¥3 873.14 |
+17%
|
| Industry Average | 3.6 | ¥1 289.69 |
-61%
|
| Country Average | 3.7 | ¥1 341.76 |
-59%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
875B JPY | 9.2 | 49.5 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 11.7 | 39.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.2B CHF | 6.6 | 36.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
89.7B DKK | 5.8 | 22.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 4.1 | 30.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | 301.8 | -37.9 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 5 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 11.5 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | 14 | 22.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | 3.3 | -15.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 2.6 |
| Median | 3.7 |
| 70th Percentile | 5.9 |
| Max | 45 735 393.8 |
Other Multiples
Asahi Intecc Co Ltd
Glance View
Asahi Intecc Co., Ltd. stands at the intersection of precision engineering and medical innovation, carving a niche in the specialized realm of guide wires and catheters, essential tools in the field of cardiovascular interventions. The company, rooted in Japan, has harnessed its expertise in ultra-fine stainless steel wire ropes—a technology initially honed for industrial purposes—to revolutionize medical devices. Unlike many in the industry, Asahi Intecc integrates its manufacturing vertically, producing components in-house to maintain high standards of quality and performance. This meticulous approach ensures that its products meet the demanding specifications of the medical community. Beyond its cornerstone medical division, the company extends its reach into industrial fields such as robotics and consumer electronics, where its high-precision capabilities are equally prized. The financial scaffolding of Asahi Intecc is built on its ability to consistently deliver innovative solutions that address the needs of an aging global population increasingly susceptible to cardiovascular ailments. Its robust R&D initiatives are pivotal in sustaining its competitive edge, fostering the development of next-generation medical devices that cater to the complex demands of advanced medical procedures. The company capitalizes on a global distribution network, allowing it to tap into burgeoning markets across Asia, Europe, and the Americas. Revenue streams are diversified across product sales, royalties, and collaborative ventures, with significant investments channeled back into research, ensuring that Asahi Intecc maintains a cycle of continuous improvement and adaptation in the fast-evolving med-tech landscape.